The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
All individuals who receive a heart transplant are at risk for developing antibody-mediated
rejection (AMR). An antibody is a protein produced by the body's immune system when it
detects a foreign substance, called an antigen. The mechanism of an antibody is to attack an
antigen. In antibody mediated rejection, antibodies will attack the transplanted heart,
causing injury to the heart. The purpose of this investigation is to determine if a study
drug, called eculizumab (Soliris), is safe to use in heart transplant recipients, and
determine if it reduces risk of antibody-mediated rejection.